

# Jochen Utikal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/151075/jochen-utikal-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225  
papers

18,417  
citations

52  
h-index

134  
g-index

249  
ext. papers

22,796  
ext. citations

7.1  
avg. IF

6.5  
L-index

#	Paper	IF	Citations
225	S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2022</b> ,	1.2	2
224	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. <b>2022</b> , 10,		1
223	MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 32-41	7.5	0
222	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.. <i>European Journal of Cancer</i> , <b>2021</b> , 161, 99-107	7.5	0
221	Timed Ang2-Targeted Therapy Identifies the Angiopoietin-Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis. <i>Cancer Discovery</i> , <b>2021</b> , 11, 424-445	24.4	12
220	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 159, 113-124	7.5	0
219	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e20708	7.6	10
218	IER2-induced senescence drives melanoma invasion through osteopontin. <i>Oncogene</i> , <b>2021</b> , 40, 6494-6510	3.2	3
217	Clinical determinants of long-term survival in metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	0
216	FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 657-674	7.5	1
215	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 1-10	7.5	4
214	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	8
213	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 139-154	7.5	4
212	Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1628-1638	7.5	2
211	TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes. <i>Scientific Reports</i> , <b>2021</b> , 11, 14689	4.9	1
210	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
209	Patient preferences for treatment of advanced melanoma: impact of comorbidities. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 58-70	1.2	2

208	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. <i>Cellular Immunology</i> , <b>2021</b> , 359, 104254	4.4	26
207	Id1 and Id3 Are Regulated Through Matrix-Assisted Autocrine BMP Signaling and Represent Therapeutic Targets in Melanoma. <i>Advanced Therapeutics</i> , <b>2021</b> , 4, 2000065	4.9	1
206	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , <b>2021</b> , 360, 104274	4.4	3
205	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
204	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e23436	7.6	7
203	Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor Tissue. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
202	Reducing the Impact of Confounding Factors on Skin Cancer Classification via Image Segmentation: Technical Model Study. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e21695	7.6	3
201	Digital Natives Preferences on Mobile Artificial Intelligence Apps for Skin Cancer Diagnostics: Survey Study. <i>JMIR MHealth and UHealth</i> , <b>2021</b> , 9, e22909	5.5	2
200	NRAS mutant melanoma: Towards better therapies. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102238	14.4	6
199	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 741993	5.3	1
198	HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
197	Cellular Reprogramming-A Model for Melanoma Cellular Plasticity. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
196	Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
195	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
194	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG <b>2020</b> , 8,		7
193	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2543-2551	2.2	13
192	Update on Alterations in Cancer: Implications for Uveal Melanoma Treatment. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
191	Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. <i>Oncolimmunology</i> , <b>2020</b> , 9, 1727116	7.2	21

190	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1023-1036	8.7	13
189	Dormant tumor cells interact with memory CD8 T cells in RET transgenic mouse melanoma model. <i>Cancer Letters</i> , <b>2020</b> , 474, 74-81	9.9	8
188	Oncogenic Role of an Epigenetic Reader of mA RNA Modification: YTHDF1 in Merkel Cell Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	20
187	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 1799-1807	5.9	7
186	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. <i>Oncotmunology</i> , <b>2020</b> , 9, 1744946	7.2	13
185	Perspective  Escape from destruction: how cancer-derived EVs are protected from phagocytosis. <i>Trillium Extracellular Vesicles</i> , <b>2020</b> , 2, 60-64	0.2	0
184	Artificial Intelligence and Its Effect on Dermatologists  Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e18091	7.6	14
183	STAT3 Relays a Differential Response to Melanoma-Associated Mutations. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
182	NF1-RAC1 axis regulates migration of the melanocytic lineage. <i>Translational Oncology</i> , <b>2020</b> , 13, 1008584.9	4.9	1
181	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> , <b>2020</b> , 585, 107-112	50.4	195
180	Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 83-99	6.4	7
179	Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
178	SOX2 in development and cancer biology. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 67, 74-82	12.7	71
177	Tumor Cell-Derived Angiopoietin-2 Promotes Metastasis in Melanoma. <i>Cancer Research</i> , <b>2020</b> , 80, 2586-2598	12.7	12
176	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	20
175	Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs. <i>IScience</i> , <b>2019</b> , 12, 168-181	6.1	15
174	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 109, 61-69	7.5	18
173	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3462-3477	7.5	28

172	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 207-215	7.5	26
171	Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 111	6.1	15
170	A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes. <i>Europace</i> , <b>2019</b> , 21, 1410-1421	3.9	15
169	Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 1020-1032	7.5	26
168	Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes. <i>Scientific Reports</i> , <b>2019</b> , 9, 5651	4.9	2
167	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , <b>2019</b> , 110, 11-20	7.5	33
166	A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 909-921	7.5	1
165	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <i>Cancer Research</i> , <b>2019</b> , 79, 4715-4728	10.1	51
164	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 760	9.8	10
163	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study <b>2019</b> , 7, 299		52
162	Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9505-9505	2.2	7
161	Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Frontiers in Cell and Developmental Biology</i> , <b>2019</b> , 7, 261	5.7	13
160	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , <b>2019</b> , 6, MMT33	2.1	2
159	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , <b>2019</b> , 25, 1916-1927	50.5	227
158	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies <b>2019</b> , 7, 343		24
157	Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells. <i>Cell Stem Cell</i> , <b>2019</b> , 24, 166-182.e13	18	24
156	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 16-25	8.7	235
155	Expression of Neural Crest Markers GLDC and ERFF1 is Correlated with Melanoma Prognosis. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7

154	Opposing roles of eosinophils in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 823-833	7.4	57
153	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 830-842	5.5	34
152	Single cell polarity in liquid phase facilitates tumour metastasis. <i>Nature Communications</i> , <b>2018</b> , 9, 887	17.4	30
151	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. <i>Oncotmunology</i> , <b>2018</b> , 7, e1445457	7.2	9
150	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 34-43	7.5	59
149	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 777-787	10.2	79
148	Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. <i>International Journal of Cardiology</i> , <b>2018</b> , 254, 195-202	3.2	35
147	Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	56
146	Multiple epidermotropic melanoma metastases developing during and inhibitor therapy. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 129-131	1.4	
145	Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , <b>2018</b> , 20, f46-f56	3.9	26
144	Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e001893	5.2	22
143	CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <i>Cancer Research</i> , <b>2018</b> , 78, 157-167	10.1	82
142	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 398	8.4	274
141	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1310	8.4	260
140	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. <i>Oncogene</i> , <b>2018</b> , 37, 6136-6151	9.2	49
139	Willingness to pay for a cure of low-risk melanoma patients in Germany. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197780	3.7	6
138	RAF-Inhibitoren. <i>Hautnah</i> , <b>2018</b> , 17, 31-38	0.2	
137	Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2962-2972	7.5	17

136	SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 3131-3142	7.5	34
135	T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 1147-1157	7.4	9
134	gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma. <i>Oncotarget</i> , <b>2018</b> , 9, 21182-21189	3.3	5
133	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , <b>2018</b> , 9, 26217-26225	3.3	3
132	The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. <i>Oncotarget</i> , <b>2018</b> , 9, 34336-34346	3.3	20
131	Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. <i>Journal of Medical Internet Research</i> , <b>2018</b> , 20, e11871	7.6	17
130	Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , <b>2018</b> , 20, e11936	7.6	140
129	Topography of cancer-associated immune cells in human solid tumors. <i>ELife</i> , <b>2018</b> , 7,	8.9	123
128	Malignes Melanom beim alten und geriatrischen Patienten <b>2018</b> , 527-534		
127	Centrifugal Surgery. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2018</b> , 115, 598	2.5	
126	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. <i>European Journal of Cancer</i> , <b>2018</b> , 88, 67-76	7.5	13
125	Tackling malignant melanoma epigenetically: histone lysine methylation. <i>Clinical Epigenetics</i> , <b>2018</b> , 10, 145	7.7	15
124	Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. <i>Cancers</i> , <b>2018</b> , 10,	6.6	8
123	Targeting SOX2 in anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , <b>2018</b> , 22, 983-991	6.4	36
122	Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Stem Cells International</i> , <b>2018</b> , 2018, 6067096	5	33
121	MicroRNAs as novel targets and tools in cancer therapy. <i>Cancer Letters</i> , <b>2017</b> , 387, 84-94	9.9	75
120	Endothelial Notch1 Activity Facilitates Metastasis. <i>Cancer Cell</i> , <b>2017</b> , 31, 355-367	24.3	161
119	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1015-1023	7.4	56

118	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1379-1391	8	25
117	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1631-1639	10.3	361
116	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). <i>Oncolmmunology</i> , <b>2017</b> , 6, e1326440	7.2	51
115	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 56-65	7.5	109
114	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 36-44	7.5	50
113	Acquired IFN $\gamma$ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , <b>2017</b> , 8, 15440	17.4	125
112	Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1907-1917	7.5	6
111	An RNAi Screen Reveals an Essential Role for HIPK4 in Human Skin Epithelial Differentiation from iPSCs. <i>Stem Cell Reports</i> , <b>2017</b> , 9, 1234-1245	8	4
110	Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 229	8.3	33
109	Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 40683-40692	3.3	53
108	RAF-Inhibitoren. <i>Onkologe</i> , <b>2017</b> , 23, 639-644	0.1	
107	Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. <i>Scientific Reports</i> , <b>2017</b> , 7, 2935	4.9	63
106	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , <b>2017</b> , 547, 222-226	50.4	1153
105	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , <b>2017</b> , 39, 295-305	12	49
104	D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 914-921	7.5	17
103	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , <b>2017</b> , 8, 76029-76043	3.3	5
102	The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. <i>Oncotarget</i> , <b>2017</b> , 8, 103682-103692	3.3	17
101	New role of ID3 in melanoma adaptive drug-resistance. <i>Oncotarget</i> , <b>2017</b> , 8, 110166-110175	3.3	13



100 Malignes Melanom beim alten und geriatrischen Patienten **2017**, 1-8

99	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. <i>ESMO Open</i> , <b>2016</b> , 1, e000068	6	34
98	Preferences of German melanoma patients for interferon (IFN) $\alpha$ 2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5375	1.8	8
97	SOX5 is involved in balanced MITF regulation in human melanoma cells. <i>BMC Medical Genomics</i> , <b>2016</b> , 9, 10	3.7	15
96	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. <i>OncolImmunology</i> , <b>2016</b> , 5, e1160183	7.2	3
95	MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2257-62	7.5	11
94	Predictive immune markers in advanced melanoma patients treated with ipilimumab. <i>OncolImmunology</i> , <b>2016</b> , 5, e1158901	7.2	16
93	TGF- $\beta$ induces SOX2 expression in a time-dependent manner in human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 453-8	4.5	21
92	Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 158-64	1.2	19
91	Differential Regulation of SOX9 Protein During Chondrogenesis of Induced Pluripotent Stem Cells Versus Mesenchymal Stromal Cells: A Shortcoming for Cartilage Formation. <i>Stem Cells and Development</i> , <b>2016</b> , 25, 598-609	4.4	30
90	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166143	3.7	21
89	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <i>Vaccines</i> , <b>2016</b> , 4,	5.3	187
88	Eignung und Probleme von Serum S100B als Biomarker zur Verlaufskontrolle bei Hochrisiko-Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 158-165	1.2	
87	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 832-46	5.8	18
86	Zweites Netzwerktreffen der zertifizierten Hauttumorzentren. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 1051-1052	1.2	
85	Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage. <i>Scientific Reports</i> , <b>2016</b> , 6, 28891	4.9	5
84	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF $\alpha$ Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. <i>Journal of Immunotherapy</i> , <b>2016</b> , 39, 343-354	5	17
83	Multiple roles of NF1 in the melanocyte lineage. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 417-25	4.5	10

82	Ethyl 2-((4-Chlorophenyl)amino)thiazole-4-carboxylate and Derivatives Are Potent Inducers of Oct3/4. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 5742-50	8.3	13
81	Function and significance of MicroRNAs in benign and malignant human stem cells. <i>Seminars in Cancer Biology</i> , <b>2015</b> , 35, 200-11	12.7	14
80	Identification of 2-[4-[(4-Methoxyphenyl)methoxy]-phenyl]acetonitrile and Derivatives as Potent Oct3/4 Inducers. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 4976-83	8.3	14
79	NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 407-16	4.5	46
78	Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons. <i>Stem Cell Research</i> , <b>2015</b> , 15, 30-41	1.6	12
77	Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 180, 467-74	6.2	26
76	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5453-9	12.9	237
75	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , <b>2015</b> , 350, 207-211	33.3	1583
74	New therapeutic options for advanced non-resectable malignant melanoma. <i>Advances in Medical Sciences</i> , <b>2015</b> , 60, 83-8	2.8	37
73	PIEZO2 is required for mechanotransduction in human stem cell-derived touch receptors. <i>Nature Neuroscience</i> , <b>2015</b> , 18, 10-6	25.5	66
72	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2352-60	7.5	112
71	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. <i>Blood</i> , <b>2015</b> , 125, 3153-63	2.2	86
70	The oak processionary moth: a new health hazard?. <i>British Journal of General Practice</i> , <b>2015</b> , 65, 435-6	1.6	10
69	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 351	8.5	47
68	Acid citrate dextrose extracorporeal photopheresis is an alternative treatment option for patients with heparin allergy. <i>International Journal of Dermatology</i> , <b>2015</b> , 54, e266-7	1.7	0
67	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2607-17	7.5	22
66	Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib. <i>Acta Dermato-Venereologica</i> , <b>2015</b> , 95, 96-7	2.2	3
65	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118564	3.7	155

64	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 444-51	4.0	926
63	Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naïve advanced metastatic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20080-e20080	2.2	
62	Extracellular adenosine metabolism in immune cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 1073-80	7.4	42
61	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. <i>Seminars in Cancer Biology</i> , <b>2014</b> , 28, 51-7	12.7	58
60	Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 431-4	4	31
59	Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-7	1.2	33
58	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1877-88	59.2	1195
57	De- and re-differentiation of the melanocytic lineage. <i>European Journal of Cell Biology</i> , <b>2014</b> , 93, 30-5	6.1	14
56	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-1027	1.2	13
55	Differential influence of vemurafenib and dabrafenib on patients lymphocytes despite similar clinical efficacy in melanoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 747-753	10.3	42
54	Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 499-510	12.9	96
53	From skin to other cell types of the body. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 789-92	1.2	4
52	Von Hautzellen zu anderen Körperzellen. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 789-793	1.2	1
51	Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. <i>Medicine (United States)</i> , <b>2014</b> , 93, e161	1.8	7
50	Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2498-9	12.9	4
49	SOX2 and cancer: current research and its implications in the clinic. <i>Clinical and Translational Medicine</i> , <b>2014</b> , 3, 19	5.7	159
48	Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e89491	3.7	18
47	Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 11-8	4.6	64

46	Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. <i>Development (Cambridge)</i> , <b>2013</b> , 140, 66-75	6.6	54
45	Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 2453-2460	4.3	48
44	Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. <i>Journal of Cell Science</i> , <b>2013</b> , 126, e1-e1	5.3	1
43	Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives. <i>Biotechnology Journal</i> , <b>2012</b> , 7, 810-21	5.6	41
42	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 107-14	59.2	1634
41	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA8509-LBA8509	2.2	10
40	Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play <b>2012</b> , 9-18		2
39	Dexamethasone cyclophosphamide pulse therapy is highly efficient in autoimmune blistering and connective tissue disorders. <i>European Journal of Dermatology</i> , <b>2011</b> , 21, 129-30	0.8	1
38	Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 665-7	4	52
37	From skin to the treatment of diseases--the possibilities of iPS cell research in dermatology. <i>Experimental Dermatology</i> , <b>2011</b> , 20, 523-8	4	26
36	Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2011</b> , 9, 212-22	1.2	7
35	Acute disseminated erythematous papulovesicular skin lesions in a 7-year-old child: a quiz. Diagnosis: vesicular Gianotti-Crosti syndrome. <i>Acta Dermato-Venereologica</i> , <b>2011</b> , 91, 491-4	2.2	4
34	Treatment of gunpowder tattoos with a high-speed diamond drill. <i>Dermatologic Surgery</i> , <b>2010</b> , 36, 939-41.7		2
33	Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sary syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2010</b> , 8, 428-38	1.2	8
32	Die Kombinationstherapie mit extrakorporaler Photopherese, Interferon-PUVA und lokalen Glukokortikoiden in der Behandlung des Sary-Syndroms. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2010</b> , 8, 428-438	1.2	14
31	Systemic therapy of non-resectable metastatic melanoma. <i>Cancers</i> , <b>2010</b> , 2, 955-69	6.6	4
30	Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. <i>Journal of Cell Science</i> , <b>2009</b> , 122, 3502-10	5.3	264
29	Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. <i>Nature</i> , <b>2009</b> , 460, 1145-8	50.4	706

28	Tumor biomarkers in melanoma. <i>Cancer Control</i> , <b>2009</b> , 16, 219-24	2.2	31
27	Sjögren syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. <i>Leukemia</i> , <b>2008</b> , 22, 393-9	10.7	80
26	Induced pluripotent stem cells generated without viral integration. <i>Science</i> , <b>2008</b> , 322, 945-9	33.3	1316
25	A high-efficiency system for the generation and study of human induced pluripotent stem cells. <i>Cell Stem Cell</i> , <b>2008</b> , 3, 340-5	18	445
24	Prognostic Biomarkers of Cutaneous Malignancies: Serological, Immunohistochemical and Proteomic Approaches. <i>Current Cancer Therapy Reviews</i> , <b>2008</b> , 4, 96-104	0.4	1
23	Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. <i>Stem Cells</i> , <b>2008</b> , 26, 2467-74	5.8	262
22	Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. <i>Archives of Dermatological Research</i> , <b>2007</b> , 298, 469-77	3.3	42
21	Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. <i>Archives of Dermatology</i> , <b>2007</b> , 143, 736-40		59
20	Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. <i>Cell Stem Cell</i> , <b>2007</b> , 1, 55-70	18	1406
19	The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2287-93	7.5	40
18	Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. <i>Immunobiology</i> , <b>2006</b> , 211, 473-86	3.4	152
17	Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 55, S92-4	4.5	10
16	Management of cutaneous type IV hypersensitivity reactions induced by heparin. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 611-617	7	29
15	Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. <i>Blood</i> , <b>2006</b> , 107, 3221-8	2.2	167
14	Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasms. <i>Journal of Cutaneous Pathology</i> , <b>2006</b> , 33 Suppl 2, 20-3	1.7	5
13	Additional Her 2/neu gene copies in patients with Sjögren syndrome. <i>Leukemia Research</i> , <b>2006</b> , 30, 755-60	2.7	11
12	Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. <i>Cancer Letters</i> , <b>2005</b> , 219, 197-204	9.9	12
11	Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. <i>Scandinavian Journal of Immunology</i> , <b>2005</b> , 61, 10-7	3.4	129

10	Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 895-6	7	15
9	Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. <i>International Journal of Oncology</i> , <b>2005</b> , 26, 597-605	1	6
8	The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. <i>Scandinavian Journal of Immunology</i> , <b>2004</b> , 60, 233-7	3-4	45
7	Molecular genetics of Xeroderma pigmentosum variant. <i>Experimental Dermatology</i> , <b>2003</b> , 12, 529-36	4	58
6	Predominant telangiectatic erythema in linear atrophoderma of Moulin: novel variant or separate entity?. <i>Dermatology</i> , <b>2003</b> , 207, 310-5	4-4	21
5	Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma. <i>Cancer Investigation</i> , <b>2002</b> , 20, 914-21	2-1	21
4	Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 72-9	8-7	91
3	Chromosome 7 Aneusomy. A Marker for Metastatic Melanoma?. <i>Neoplasia</i> , <b>2001</b> , 3, 245-254	6-4	54
2	c-MYC and nodular malignant melanoma. A case report. <i>Cancer</i> , <b>2000</b> , 89, 97-103	6-4	23
1	Skin Cancer Classification using Convolutional Neural Networks: Systematic Review (Preprint)		4